阿奇霉素与红霉素治疗小儿支原体肺炎临床对照观察  

Controlled Study of Azithromycin and Erythromycin in the Treatment of Mycoplasma Pneumonia in Children

作　　者：陈海生[1] 濮泽琼[1] 张梅虹[1] 

机构地区：[1]复旦大学附属金山医院儿科,上海200540

出　　处：《中国临床医学》2004年第4期535-536,共2页Chinese Journal of Clinical Medicine

摘　　要：目的 :探讨阿奇霉素与红霉素治疗小儿支原体肺炎的临床疗效及安全性。方法 :将明确诊断为支原体肺炎的 70例住院患儿随机分成阿奇霉素组 (治疗组 )和红霉素组 (对照组 ) ,比较分析 2组患儿的平均住院天数、退热时间、咳嗽好转时间、罗音消失时间、不良反应率以及住院总费用。结果 :阿奇霉素治疗小儿支原体肺炎的平均住院天数、咳嗽好转时间、罗音消失时间、不良反应率均较红霉素治疗组明显减少或缩短 ,有显著差异 ,而退热时间、住院总费用则无显著差异。结论 :阿奇霉素治疗小儿支原体肺炎疗效明显 ,安全可靠 。Objective: To study the efficacy and safety of Azithromycin and Erythromycin in the treatment of mycoplasma pneumonia in children. Methods: The 70 hospitalized children, who have already been diagnosed to be infected by mycoplasma pneumonia, are divided into two groups, Azithromycin group (treatment group) and the erythromycin group (control group), in casual way. Comparative analysis are carried on in the following aspects: the average hospitalized days, the days for thd drawback of fever, the recovery days of coughs, days for the disappearance of rale, the frequency of negative reaction and the total expense of hospitalization. Results: In comparison with erythromycin group, it takes Azithromycin group much shorter time in respect of the average hospitalized days, the recovery days of coughs, days for the disappearance of rale and the negative reaction happens less frequent. And there is not obvious difference in the days for the drawback of fever and the total expense of hospitalization. Conclusion:The Azithromycin is quite effective and safe in the treatment of child's mycoplasma pnuemonia. It deserve to be applied in the clinical treatment.

关 键 词：阿奇霉素 红霉素 治疗 小儿 支原体肺炎 安全性 

分 类 号：R725.631[医药卫生—儿科]